Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 9,417 shares, a growth of 116.0% from the August 15th total of 4,359 shares. Based on an average daily trading volume, of 10,401 shares, the short-interest ratio is presently 0.9 days.
Defence Therapeutics Trading Down 2.2%
Shares of DTCFF opened at $0.33 on Tuesday. Defence Therapeutics has a 52 week low of $0.25 and a 52 week high of $0.78. The stock has a fifty day moving average of $0.33 and a 200-day moving average of $0.37.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Featured Stories
- Five stocks we like better than Defence Therapeutics
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
